Family Medicine Doctors in Winchester, MA Accepting Medicare

10 Family Medicine doctors found. Showing 1 - 10

Jose A Guerra, M.D. Family Medicine - Adolescent Medicine Medicare: Accepting Medicare Assignments Practice Location: 11 Shore Rd, Winchester, MA 01890 Phone: 781-729-1810

Dr. Dennis I Markovitz, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 259 Swanton St, Winchester, MA 01890 Phone: 781-721-4616    Fax: 781-721-2687

Joel Solomon, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 11 Shore Rd, Winchester, MA 01890 Phone: 781-729-1810    Fax: 781-729-2117

Catherine S. Celler, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11 Shore Road, Winchester, MA 01890 Phone: 781-729-1810    Fax: 781-729-4577

Hilda Ag Rock, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11 Shore Rd, Winchester, MA 01890 Phone: 781-729-1810

Wellner Poppe, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 11 Shore Rd, Winchester, MA 01890 Phone: 781-729-1810    Fax: 781-729-4577

Heather T Jones, MD Family Medicine - Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 11 Shore Rd, Winchester, MA 01890 Phone: 781-729-1810    Fax: 866-777-2310

Jeffrey G Miner, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11 Shore Road, Winchester, MA 01890 Phone: 781-729-1810    Fax: 978-683-0663

Keri Layton, N.D Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 10 Converse Pl, Suite 101, Winchester, MA 01890 Phone: 781-721-4585

Dr. Morgan Santhamoorthy, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 203 Cambridge St, Winchester, MA 01890 Phone: 781-879-6794

News Archive

Alimera submits Iluvien NDA for DME to FDA

Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Iluvien®, (flucocinolone acetonide intravitreal insert), its investigational, sustained drug delivery system releasing sub-microgram levels of fluocinolone acetonide for the treatment of diabetic macular edema (DME).

New approach reduces JAK2 activity by pharmacologically targeting HSP90 protein

Myeloproliferative neoplasms (MPN) comprise a family of blood cancers characterized by clonal expansion of a single blood cell type. Untreated, these cancers can progress to bone marrow failure and acute myeloid leukemia. Several groups have identified activating mutations in the JAK2 gene as associated with MPN; JAK2 inhibition has therefore emerged as approach to MPN therapy.

Jubilant Organosys, UAB and Southern Research Institute announce joint venture to accelerate global drug development

Jubilant Organosys, the University of Alabama at Birmingham (UAB), and Southern Research Institute today announced a joint venture that will focus on leveraging their collective innovation and enabling technologies in the areas of Oncology, Metabolic Disease and Infectious Diseases. It is a unique U.S.-India arbitraged and leveraged partnership that will accelerate the development of affordable therapies for patients worldwide.

Lilly's ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis.

Read more Medical News

› Verified 2 days ago